Vuja De develops a proprietary anti-metastatic progression discovery platform that targets the unique vulnerability of dormant micro-metastatic tumors, which contribute to cancer recurrence. The company's treatments aim to prevent the progression of osteosarcoma and other cancers, significantly reducing mortality rates associated with cancer recurrence.
Funding
$4.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metastatic cancer recurrence, often arising from dormant micro-metastatic tumors, is a major cause of cancer-related deaths. These dormant tumors can persist for extended periods before reactivating and spreading, making them difficult to target with conventional therapies.
Solution
Vuja De is developing a platform to discover and develop drugs that target the unique vulnerabilities of dormant micro-metastatic tumors, preventing cancer recurrence and progression. The company's approach focuses on "Metastatic Endurance," a characteristic of these persistent tumors. By targeting this vulnerability, Vuja De aims to prevent the spread of cancer and improve patient outcomes. The platform identifies drugs that can disrupt the mechanisms allowing these tumors to remain dormant and then reactivate.
Target Audience
The primary target audience includes patients at risk of cancer recurrence, as well as oncologists and researchers seeking new therapies to prevent metastasis.
Features
- Proprietary anti-metastatic progression discovery platform
- Focus on targeting "Metastatic Endurance" of dormant micro-metastatic tumors
- Aims to prevent cancer recurrence and spread